Application of 14-3-3 sigma in colon cancer treatment
The invention discloses an application of 14-3-3 sigma in colon cancer treatment. Starting from a hypoxia tumor microenvironment for promoting colon cancer metastasis and angiogenesis, the relationship between the adaptive protein 14-3-3 sigma and colon cancer metastasis and prognosis is researched,...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
01.12.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The invention discloses an application of 14-3-3 sigma in colon cancer treatment. Starting from a hypoxia tumor microenvironment for promoting colon cancer metastasis and angiogenesis, the relationship between the adaptive protein 14-3-3 sigma and colon cancer metastasis and prognosis is researched, and the condition that the 14-3-3 sigma regulates hypoxia-mediated colon cancer metastasis and angiogenesis by regulating HIF-1alpha and promotes the drug sensitivity of bevacizumab is further clarified; mechanism research proves that 14-3-3 sigma and E3 ubiquitin ligase NEDD4L are combined to form a protein complex to regulate and control signal transduction of HIF-1alpha ubiquitination proteasome degradation, and finally the value of combined expression of 14-3-3 sigma and HIF-1alpha in the aspect of colon cancer prognosis is proved.
本发明公开了一种14-3-3σ在结肠癌治疗中的应用。本发明从促进结肠癌转移与血管生成的乏氧肿瘤微环境入手,探究适应性蛋白14-3-3σ与结肠癌转移和预后之间的联系,进一步阐明14-3-3σ通过调控HIF-1α来调节乏氧介导的结肠癌转移与血管生成并促进贝伐珠单抗的药物敏感性,机制研究证实14-3-3σ与E3泛素连接酶NEDD4L结合形成蛋白复合体调控HIF-1α |
---|---|
AbstractList | The invention discloses an application of 14-3-3 sigma in colon cancer treatment. Starting from a hypoxia tumor microenvironment for promoting colon cancer metastasis and angiogenesis, the relationship between the adaptive protein 14-3-3 sigma and colon cancer metastasis and prognosis is researched, and the condition that the 14-3-3 sigma regulates hypoxia-mediated colon cancer metastasis and angiogenesis by regulating HIF-1alpha and promotes the drug sensitivity of bevacizumab is further clarified; mechanism research proves that 14-3-3 sigma and E3 ubiquitin ligase NEDD4L are combined to form a protein complex to regulate and control signal transduction of HIF-1alpha ubiquitination proteasome degradation, and finally the value of combined expression of 14-3-3 sigma and HIF-1alpha in the aspect of colon cancer prognosis is proved.
本发明公开了一种14-3-3σ在结肠癌治疗中的应用。本发明从促进结肠癌转移与血管生成的乏氧肿瘤微环境入手,探究适应性蛋白14-3-3σ与结肠癌转移和预后之间的联系,进一步阐明14-3-3σ通过调控HIF-1α来调节乏氧介导的结肠癌转移与血管生成并促进贝伐珠单抗的药物敏感性,机制研究证实14-3-3σ与E3泛素连接酶NEDD4L结合形成蛋白复合体调控HIF-1α |
Author | YANG RUNXIANG LI MENGHONG LIU SICHENG |
Author_xml | – fullname: YANG RUNXIANG – fullname: LIU SICHENG – fullname: LI MENGHONG |
BookMark | eNrjYmDJy89L5WQwdSwoyMlMTizJzM9TyE9TMDTRNdY1VijOTM9NVMjMU0jOzwFKJCfmJacWKZQUpSaW5KbmlfAwsKYl5hSn8kJpbgZFN9cQZw_d1IL8-NTigsTk1LzUknhnP0NDc0MTEwMDE0djYtQAAKttLVc |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences Physics |
DocumentTitleAlternate | 14-3-3σ在结肠癌治疗中的应用 |
ExternalDocumentID | CN117144004A |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_CN117144004A3 |
IEDL.DBID | EVB |
IngestDate | Fri Sep 06 06:15:39 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | Chinese English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_CN117144004A3 |
Notes | Application Number: CN202310903224 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231201&DB=EPODOC&CC=CN&NR=117144004A |
ParticipantIDs | epo_espacenet_CN117144004A |
PublicationCentury | 2000 |
PublicationDate | 20231201 |
PublicationDateYYYYMMDD | 2023-12-01 |
PublicationDate_xml | – month: 12 year: 2023 text: 20231201 day: 01 |
PublicationDecade | 2020 |
PublicationYear | 2023 |
RelatedCompanies | THE SIXTH AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY |
RelatedCompanies_xml | – name: THE SIXTH AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY |
Score | 3.6431262 |
Snippet | The invention discloses an application of 14-3-3 sigma in colon cancer treatment. Starting from a hypoxia tumor microenvironment for promoting colon cancer... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE |
Title | Application of 14-3-3 sigma in colon cancer treatment |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231201&DB=EPODOC&locale=&CC=CN&NR=117144004A |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQsTRNSUw2M0jVNTU1NtcFtm-BeS7ZxFg3ycwy2SwRiA3Ap-37-pl5hJp4RZhGMDFkwfbCgM8JLQcfjgjMUcnA_F4CLq8LEINYLuC1lcX6SZlAoXx7txBbFzVo7xjYWAFWaGouTrauAf4u_s5qzs62zn5qfkG2hqCLvkHp1ZGZgRXUjAads-8a5gTalVKAXKW4CTKwBQBNyysRYmCqyhBm4HSG3bwmzMDhC53wFmZgB6_QTC4GCkJzYbEIg6kjYtZZIT9NwdBE11jXWKE4Mz03USEzTwF0EDWQBMVnkQJ8Jbkog6Kba4izhy7QJfFwb8c7-yEcbSzGwJKXn5cqwaAAGgOwTDE3T00xBrZlkhOBQZ2YYphoZJRsaWKRkmgpySCF2xwpfJLSDFygIIQs1pBhYCkpKk2VBVa5JUly4LACAGMnguM |
link.rule.ids | 230,309,786,891,25594,76904 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQsTRNSUw2M0jVNTU1NtcFtm-BeS7ZxFg3ycwy2SwRiA3Ap-37-pl5hJp4RZhGMDFkwfbCgM8JLQcfjgjMUcnA_F4CLq8LEINYLuC1lcX6SZlAoXx7txBbFzVo7xjYWAFWaGouTrauAf4u_s5qzs62zn5qfkG2hqCLvkHp1ZGZgdUc2CUEnbPvGuYE2pVSgFyluAkysAUATcsrEWJgqsoQZuB0ht28JszA4Qud8BZmYAev0EwuBgpCc2GxCIOpI2LWWSE_TcHQRNdY11ihODM9N1EhM08BdBA1kATFZ5ECfCW5KIOim2uIs4cu0CXxcG_HO_shHG0sxsCSl5-XKsGgABoDsEwxN09NMQa2ZZITgUGdmGKYaGSUbGlikZJoKckghdscKXyS8gycHiG-PvE-nn7e0gxcoOCELNyQYWApKSpNlQVWvyVJcuBwAwCofIXO |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Application+of+14-3-3+sigma+in+colon+cancer+treatment&rft.inventor=YANG+RUNXIANG&rft.inventor=LIU+SICHENG&rft.inventor=LI+MENGHONG&rft.date=2023-12-01&rft.externalDBID=A&rft.externalDocID=CN117144004A |